<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528448</url>
  </required_header>
  <id_info>
    <org_study_id>NPE-01-2014</org_study_id>
    <nct_id>NCT02528448</nct_id>
  </id_info>
  <brief_title>0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis</brief_title>
  <acronym>KIPA</acronym>
  <official_title>The Effect of 0,9% NaCl on the Kidney Function, Vasoactive Hormones, Biomarkers and Glycosaminglycanes in Plasma in Patients Operated on for Primary Hiparthrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if chloride is nephrotoxic using 0,9% saline versus&#xD;
      Plasma-Lytein in patients having primary hip replacement surgery. The outcome is found&#xD;
      measuring bio markers, vasoactive hormones and salt regulation. And to measure syndecan as a&#xD;
      marker for glycocalyx degradation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      Chloride has a nephrotoxic effect, which can be shown partially by measuring bio markers for&#xD;
      tubular injury in urine, partially by the changes in tubular transport of sodium and water in&#xD;
      different parts of the nephron. This can be demonstrated using isotone sodium solutions with&#xD;
      a lower chloride concentration in this study plasma-lyte versus normal isotone saline.&#xD;
&#xD;
      Klorid has a toxic effect on the glycocalyx layer and leads to a rise in syndecan 1 and&#xD;
      simultaneously a change in Salt Blood Test either by a direct simulation and ANP levels in&#xD;
      plasma or as a consequence of the hyperchloremic acidosis. This can be demonstrated using&#xD;
      isotone sodium solutions with a lower chloride concentration in this study plasma-lyte versus&#xD;
      normal isotone saline.&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      The purpose is to observe changes in bio markers, vasoactive hormones and salt regulation in&#xD;
      patients randomized to either 0,9% saline or plasma-lyte undergoing primary uncemented hip&#xD;
      replacement surgery.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      40 patients undergoing primary uncemented hip replacement surgery will be randomized to&#xD;
      either 0,9% saline or plasma-lyte for standard fluid resuscitation and blood loss replacement&#xD;
      in this controlled and double blinded study. The patients will deliver a 24 hour urine sample&#xD;
      before surgery and approximately 10 days after. From the start of the surgery and to the day&#xD;
      after all urine will be collected and blood samples will be taken.&#xD;
&#xD;
      Perspective:&#xD;
&#xD;
      If chloride is found to be nephrotoxic it could lead to a general change in fluid&#xD;
      resuscitation recommendations in critically ill patient, patients with kidney disease and&#xD;
      patients undergoing surgery. It will also expand our knowledge about the permeability of the&#xD;
      blood vessels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary excretion of Neutrophil gelatinase-associated lipocalin</measure>
    <time_frame>two days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma Syndecan-1</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma renin concentration</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of cyclic guanosine monophosphate</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of epithelial sodium channels</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of water channels</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of angiotensin 2</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of aldosterone</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of atrial natriuretic peptide (ANP)</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of brain natriuretic peptide (BNP)</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of cyclic guanosine monophosphate (cGMP)</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of endothelin</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of vasopressin (AVP, ADH)</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of Fatty acid-binding protein</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of Kidney Injury Molecule</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free water clearance</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of albumin</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of chloride</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of creatinine</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma osmolarity</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of sodium</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of potassium</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of creatinine</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of chloride</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of sodium</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of potassium</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional urinary sodium excretion</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary osmolarity</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of albumin</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of sodium-chloride symporter</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>middle arterial pressure</measure>
    <time_frame>two days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Nephrotoxicity</condition>
  <arm_group>
    <arm_group_label>plasma-lyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0,9% saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous 1 hour infusion of 0,9% saline15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasma-lyte</intervention_name>
    <description>Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement</description>
    <arm_group_label>plasma-lyte</arm_group_label>
    <other_name>ATC: B 05 BB 01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0,9% saline</intervention_name>
    <description>Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement</description>
    <arm_group_label>0,9% saline</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indication for uncemented primary hiparthroplasty&#xD;
&#xD;
          -  age &lt; 60&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blooddonation or transfusion during the last month&#xD;
&#xD;
          -  Not willing to participate&#xD;
&#xD;
          -  estimated GFR below 30ml/min&#xD;
&#xD;
          -  type 1 diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper N Bech, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erling B Perdersen, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niels Peter Ekeløf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas N Jørgensen, MD</last_name>
    <phone>78436589</phone>
    <email>andrjr@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Research, Regional Hospital Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>Vasoactive hormones</keyword>
  <keyword>bio markers</keyword>
  <keyword>salt regulation</keyword>
  <keyword>Renal variables</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

